- Home
- NEGG vs ZURA Comparison
NEGG vs ZURA Comparison
Compare NEGG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | ZURA |
|---|---|---|
| Founded | 2001 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 252.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEGG | ZURA |
|---|---|---|
| Price | $50.52 | $5.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 122.1K | ★ 549.2K |
| Earning Date | 04-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,313,127,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.32 | $0.97 |
| 52 Week High | $137.84 | $5.62 |
Technical Indicators
Market Signals| Indicator | NEGG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 76.60 |
| Support Level | $53.32 | $4.00 |
| Resistance Level | $56.79 | $5.62 |
| Average True Range (ATR) | 4.31 | 0.35 |
| MACD | -0.83 | 0.12 |
| Stochastic Oscillator | 0.00 | 80.67 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.